Clinical Pharmacokinetics of Meloxicam

@article{Davies1999ClinicalPO,
  title={Clinical Pharmacokinetics of Meloxicam},
  author={N. M. Davies and N. Skjodt},
  journal={Clinical Pharmacokinetics},
  year={1999},
  volume={36},
  pages={115-126}
}
  • N. M. Davies, N. Skjodt
  • Published 1999
  • Medicine
  • Clinical Pharmacokinetics
  • Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclooxygenase-2.Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its… CONTINUE READING
    Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety
    • 55
    Pharmacokinetics of meloxicam in plasma and urine of horses.
    • 77
    • PDF
    Detection and prevention of NSAID-induced enteropathy.
    • 113
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 27 REFERENCES
    Clinical pharmacokinetics of meloxicam.
    • 44